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Abstract 
The objective of this study was to investigate whether docosahexaenoic (DHA) and 
eicosapentaenoic (EPA) acids can directly regulate glucose and fat metabolism in skeletal muscle, 
besides exerting anti-inflammatory properties. To accomplish this, L6 skeletal muscle cells were 
treated with 50µM of either DHA or EPA for 1, 3, and 5 days. Subsequently, we assessed glucose 
uptake, glycogen synthesis, lactate production, glucose and palmitate oxidation, as well as the 
phosphorylation and contents of proteins involved in insulin signalling and regulation of cellular 
oxidative capacity. mRNA expression of several genes involved in inflammation was also 
measured after DHA or EPA treatment. We found that basal rates of glucose uptake and glycogen 
synthesis as well as protein kinase B (AKT) and glycogen synthase kinase 3 (GSK3) 
phosphorylation remained unaffected by DHA or EPA. In addition, similar findings were observed 
under insulin-stimulated conditions. However, glucose and palmitate oxidation rates were 
consistently increased (day 1 to 5) by DHA treatment, whereas EPA only increased this variable 
transiently (day 1). Similarly, only DHA caused significant and sustained increases in AMP-
activated protein kinase (AMPK) phosphorylation and contents of carnitine-palmitoyl transferase 
1b (CPT1b) and peroxisome proliferator-activated receptor gamma coactivator 1α (PGC-1α) in 
skeletal muscle cells. DHA also had a more potent anti-inflammatory effect than EPA in these 
cells. In conclusion, besides exerting anti-inflammatory effects, DHA and EPA directly regulated 
glucose and fat metabolism in skeletal muscle cells, although DHA was more potent in doing so 
than EPA. Thus, by directly enhancing glucose and fat oxidation, DHA may increase glucose 
disposal and protect skeletal muscle cells against lipotoxicity.   
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Introduction 
Omega-3 fatty acids are well known for their beneficial health effects. There are a variety 
of -3 fatty acids; however, docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) 
represent those with the greatest therapeutic potential1. -3 fatty acids have therapeutic value for 
conditions that are characterized by chronic inflammation such as ulcerative colitis2, rheumatoid 
arthritis3, and atherosclerosis4 among many others. With the drastic rise in the global prevalence 
of obesity and type-2 diabetes (T2D), there is a greater focus on the potential role that -3 fatty 
acids can play in ameliorating these inflammation-induced metabolic disorders. Although human 
studies have generally been equivocal, there are several studies that provide support for the role 
that -3 fatty acids have in improving glucose tolerance in healthy humans, as well as in those 
with metabolic syndrome5–7. It was first noted that among Alaskan natives, higher consumption of 
-3-rich fish was associated with a lower incidence of glucose intolerance and T2D8. To gain a 
better understanding of the physiological importance of -3 fatty acids, numerous animal and cell 
culture studies were conducted. To identify the specific effects of -3 fatty acids, a portion of mice 
consuming a high-fat (HF) diet, had 7.5% of their calories replaced with fish oil. The deleterious 
effects of a HF diet on energy metabolism were reversed in fish oil-fed mice in part by facilitating 
the upregulation of proteins involved in lipolysis and lipid oxidation in skeletal muscle9. Besides 
having a positive effect on fat metabolism, there is evidence to suggest that insulin signalling can 
be improved as well. Rats who were fed a HF diet supplemented with 3.4% of calories coming 
from EPA and DHA had lower blood glucose and higher skeletal muscle expressions of GLUT4, 
GYS1, and IRS1 than rats fed a pure HF diet10. Evidently, -3 fatty acids are implicated in glucose 
and fat metabolism and it appears that their method of action involves the manipulation of skeletal 
muscle. Importantly, this tissue accounts for ~40% of body weight in men and ~30% in women 
2 
 
and it is responsible for ~80% of post-prandial glucose disposal11. Skeletal muscles are also highly 
adaptable to environmental factors which include alterations to physical activity and diet12. For 
these reasons, the impact of -3 fatty acids on skeletal muscle energy metabolism can potentially 
be of therapeutic value for the treatment and prevention of metabolic disorders. With regard to 
insulin resistance, the emerging etiological theory is based on excessive intramuscular triglyceride 
and lipid intermediate accumulation, leading to chronic inflammation that disrupts muscle energy 
metabolism. In fact, the lipid intermediate, diacylglycerol, can stimulate protein kinase C, leading 
to the phosphorylation of serine residues on insulin receptor substrate 1 (IRS-1) and impairment 
of insulin signalling within skeletal muscle tissue13,14. Indeed, rodent studies have shown that a HF 
diet can induce glucose intolerance in as little as 3 days15. Thus, an agent that decreases the 
accumulation of harmful lipid intermediates through the enhancement of fat metabolism may act 
to prevent insulin resistance. Previous studies support the notion that EPA and DHA can mitigate 
the detrimental effects of a HF diet on skeletal muscle tissue. Fish oil supplementation was 
associated with a reduced accumulation of lipid mediators such as ceramides and long chain acyl-
CoAs in skeletal muscle tissue of mice fed a HF diet10. However, the literature does not provide a 
detailed evaluation of the molecular mechanisms that underlie these changes.   
Ω-3 fatty acids are, however, most well known as powerful anti-inflammatory agents that 
can reduce whole-body inflammation. Oh et al. demonstrated that ω-3 fatty acids can serve as 
ligands for GPR120, which is a receptor that is mainly expressed in adipocytes, hepatocytes, and 
macrophages. Through this process, ω-3 fatty acids can inhibit tumor necrosis factor alpha (TNF-
α) and toll-like receptor (TLR) inflammatory pathways as well as reduce the expression of 
interleukin-6 (IL-6) and other inflammatory genes. Moreover, mice that had a GPR120 knockout 
demonstrated glucose intolerance and skeletal muscle insulin resistance16. In the context of muscle 
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metabolism, EPA can serve as a ligand that binds to and activate peroxisome proliferator-activated 
receptor gamma (PPARγ) thereby suppressing the activity of nuclear factor kappa light chain 
enhancer of activated B cells (NF-κB). Treatment of cultured C2C12 myoblasts, with 50 µM EPA 
for 24 h reduced IL-6 secretion  and mitigated the damaging effects of TNF-α induced 
inflammation on differentiation17. Clearly, EPA has anti-inflammatory capabilities and, through 
this process, can potentially serve as a mechanism that facilitates muscle energy metabolism18. 
However, in many studies, EPA and DHA are either grouped together9,10,19,20 or only one of the 
two is presented17,21 which prevents a detailed comparison of their independent effects. There is 
evidence to support the idea that the various -3 fatty acids can have different metabolic functions. 
For instance, one study suggests that EPA has a stronger effect than DHA on skeletal muscle 
protein metabolism in C2C12 myotubes22. However, another study reported that EPA was actually 
less efficient than DHA in inhibiting protein degradation in C2C12 myotubes23. Thus, EPA and 
DHA can behave differently and the literature is limited in exploring their relative effects on 
skeletal muscle inflammation and energy metabolism. 
For these reasons, the overall aim of this study was to address the underlying molecular 
mechanisms that are involved in EPA and DHA’s independent regulation of skeletal muscle 
inflammatory genes as well as lipid and glucose metabolism. This was done through a 5-day time-
course treatment of cultured L6 myoblasts, which assessed EPA and DHA’s relative effects on 
skeletal muscle function.  
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Literature review 
Digestion of fats 
Around 95% of the lipids consumed by humans are triacylglycerols. This macromolecule 
consists of a glycerol backbone that is esterified to three fatty acids. In order to be properly 
absorbed and utilized by the body, fats need further digestion and hydrolysis24. Teeth begin the 
physical breakdown of food and saliva serves as the liquid medium that facilitates chewing and 
swallowing25. The majority of saliva is produced from the submandibular, sublingual, and parotid 
salivary glands. The presence of salivary lipase as a lipolytic enzyme has been disputed in the 
literature with older work arguing that it is non-existant26. However, more recent and 
comprehensive analysis suggests that there are indeed various lipases that are released and mixed 
with the saliva to begin partial breakdown of triglycerides27–30. Since oral lipases are present in 
such small quantities, they are not significant contributors to fat digestion31. This process usually 
takes between one and five seconds and is enough time to be able to taste the fat present in 
foods32,33. Therefore, from an evolutionary perspective, the function of oral lipases is likely to 
facilitate the identification of energy rich foods that are high in fat32,34. Once the food forms into a 
bolus and is swallowed, the esophageal smooth muscle constricts in a wave-like manner to propel 
the food towards the stomach. The bolus then enters through the cardiac sphincter into the stomach.  
Here, the bolus is exposed to an extremely hostile chemical environment. Gastric acid is 
secreted by parietal cells of the stomach to facilitate digestion. Gastric acid is mainly composed of 
water, enzymes, electrolytes, and hydrochloric acid. The latter component is responsible for the 
low pH of the stomach interior. The maintenance of this acidic environment is critical for many 
digestive processes, one of which is protein denaturation35. This allows for lipid molecules to 
dissociate from proteins which improves the access that lipases have to them. However, the water-
soluble nature of gastric and pancreatic lipases presents a barrier to their interactions with lipids. 
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The stomach forcefully breaks down its contents through the constricting and churning action of 
the gastric musculature. This causes an oil in water emulsification which helps lipases to overcome 
aqueous barrier and engage in lipid hydrolysis36,37. The products of gastric lipid digestion are 
unesterified fatty acids, diacylglycerols and monoacylglycerols among many other nutrients that 
combine together in an acidic mixture termed chyme.  
The stomach’s contribution to fat digestion and the human’s overall capacity to digest fat is 
greatly influenced by physiological maturation and health status. Once emerging from the womb 
and beginning to feed on breast milk, infants must deal with the demanding process of fat digestion. 
As an infant, with minimal production of bile salts from the liver and lipase from the pancreas, 
digestion of fats presents a significant challenge. Nonetheless, the properties of breast milk 
optimize its own digestion due to the presence of bile-salt stimulated lipase. This lipase maximizes 
the efficiency of the small amount of bile-salts that are produced by infants. Like adults, infants 
also secrete gastric lipase; however, unlike adults, the infant’s accessory organs are not fully 
developed and therefore rely heavily on gastric lipase to break down lipids38. Moreover, health 
conditions that compromise the function of the pancreas, such as pancreatitis and cystic fibrosis, 
lead to an increased reliance on the stomach for fat digestion39. However, in an otherwise healthy 
individual, once consumption of solid foods begins, the primary location of fat digestion shifts to 
the duodenum. In fact, among healthy adults, only 10-30% of fat digestion occurs in the 
stomach40,41. 
Thus, as the solution exits the stomach through the pyloric sphincter, it enters the duodenum. 
The presence of free fatty acids within the chyme is sensed by duodenal receptors, triggering the 
release of cholecystokinin (CCK) which leads to a series of responses. CCK causes the pylorus to 
contract and the body and the fundus of the stomach to relax which ultimately delays stomach 
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emptying and prolongs gastric digestion42. CCK also binds to CCK1 receptors that induce satiety. 
In addition, pancreatic lipase is released which is a major contributor towards lipolysis. CCK also 
promotes gall bladder contraction which leads to the release of concentrated bile. Bile is a 
substance that is composed of 95% water, however, it also contains bile salts, cholesterol, bilirubin 
phospholipids, vitamins, and minerals43. The alkaline bile helps to neutralize the acidic chyme 
within the duodenum. In the context of fat metabolism, the amphipathic nature of bile salts allows 
for further emulsification of dietary fat which facilitates the access of the primary lipolytic enzyme, 
pancreatic lipase, to its substrate. However, the bile salt itself inhibits pancreatic lipase. For this 
reason, the pancreas also secretes colipase which enables the interaction between pancreatic lipase 
and the bile salt-lipid complex44,45. As a consequence, pancreatic lipase is able to engage in lipid 
hydrolysis and produce monoglycerols, free fatty acids, and glycerol molecules. Knowledge of 
this physiological machinery allows for its manipulation in order to manage physiological 
dysfunction. For instance, Orlistat is a drug that has been proposed as a method to manage obesity 
through its ability to bond to serine residues within the active sites of pancreatic and gastric lipases, 
thereby inhibiting their function46,47. This ultimately lowers lipolysis, decreases the absorption of 
fat, and increases fat excretion48. However, this also means that the free fatty acid product would 
be produced in lesser quantities which can have a detrimental downstream effect. 
Nonetheless, the products of TAG breakdown exit the intestinal lumen and enter intestinal 
epithelial cells called enterocytes through a variety of pathways. Predominantly, this occurs 
through passive diffusion into the enterocyte, however, this process is highly dependant on the 
saturation of the phospholipid membrane. Lysophosphatidylcholine acyltransferase (LPCAT) is 
an enzyme that is responsible for the reacylation and addition of polyunsaturated fatty acids to the 
membrane. Mouse models that have a LPCAT gene knockout lead to diminished presence of 
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unsaturated fatty acids in the enterocyte membrane. Dietary deficiency in essential fatty acids also 
leads to less incorporation of unsaturated fatty acids into the lipid bilayer. In both cases, fat 
malabsorption stems from insufficient unsaturation of the enterocyte phospholipid membrane49. 
Aside from passive diffusion, there are numerous proteins that are also implicated in intestinal 
lipid absorption. The most prevalent is CD36, which is a protein that is highly expressed in the 
small intestine, muscle tissue, and adipose tissue. These peripheral tissues rely heavily on CD36 
for adequate fatty acid uptake, whereas passive diffusion is more common for intestinal fat 
absorption49. In fact, mice with CD36 knockouts still had normal levels of circulating TAG of 
intestinal origin. Despite the intestine’s apparent independence, CD36 has still shown to be 
particularly important for the uptake of very long chain fatty acids49. 
 Once inside the enterocyte, lipids are then transferred to the endoplasmic reticulum where 
TAGs are resynthesized. This is done through the help of monoacylglycerol acyltransferase 
(MGAT) and diacylglycerol transferase (DGAT). Apo B48 and many other proteins are added for 
structural and recognition purposes. Finally, cholesterol is added and this structure of lipids and 
proteins is packaged into a prechylomicron transport vesicle (PCTV) to be sent to the Golgi 
complex. There, it undergoes further modification until it leaves the Golgi as a mature 
chylomicron, undergoes exocytosis from the basolateral enterocyte membrane, and enters the 
lymphatic system (figure 1). Chylomicrons travel along lymphatic vessels and enter the circulatory 
system through the thoracic duct where they deposit TAGs and cholesterol in peripheral tissues. 
In order for chylomicrons to be utilized by peripheral tissues, they must be hydrolyzed. For this 
reason, endothelial cells of capillaries that are next to muscle, adipose, and heart tissue contain 
lipoprotein lipase which isolates the fatty acids from the rest of the chylomicron. For this process 
to occur, Apo C-II is required as a cofactor and is carried by the chylomicron itself. After lipolysis, 
8 
 
the fatty acids enter the tissue through the use of CD36 and other fatty acid transport proteins. The 
remaining chylomicron remnant is recycled by the liver and the cholesterol that is present is used 
for the production of bile acids or very low density lipoprotein (VLDL). Similar to chylomicrons, 
VLDL is composed of triglycerides and cholesterol, however, this is done in the hepatocyte 
endoplasmic reticulum and Apo B-100 is required for its synthesis50. VLDL particles travel to 
peripheral tissues where it competes with chylomicrons for access to LPL in order to undergo fatty 
acid hydrolysis. Once triglycerides are removed from the VLDL particle, VLDL remnants remain 
which are termed intermediate density lipoproteins (IDL)50. Similar to chylomicron remnants, IDL 
is cleared by the liver, however not as effectively, and approximately 50% of IDL remains in 
circulation. Through the use of hepatic lipase, the liver lowers the lipid content of the IDL 
molecules and several apolipoproteins are exchanged which leads to the creation of low density 
lipoprotein (LDL)50. Therefore, the predominant lipid in LDL is cholesterol and it is recognized 
by many tissues that have the LDL receptor. The liver, however, is the major tissue responsible 
for the clearance of circulating LDL. The abundance of LDL receptors that a cell has is inversely 
proportional to the amount of cholesterol found within that cell. Once inside, the lipoprotein is 
degraded by lysozymes leading to the release of cholesterol in the tissue. This decreases the 
expression of HMG-CoA reductase, a critical enzyme for cholesterol synthesis, thereby leading to 
less endogenous cholesterol synthesis. HDL cholesterol is formed from Apo A-I as well as 
cholesterol and phospholipids that are obtained from enterocytes, hepatocytes, and many other 
peripheral tissues. ABCA1 allows the transfer of cholesterol to Apo A-I molecules, whereas 
ABCG1 accomplishes this role for mature HDL molecules. Moreover, HDL can obtain cholesterol 
from VLDL and chylomicrons when they are being hydrolyzed by LPL. Therefore, HDL and LDL 
9 
 
have opposing functions in the body, with the former extracting cholesterol from tissues, and the 
latter transporting cholesterol to tissues.  
Figure 1: Outline of intestinal lipid absorption. The products of TAG breakdown enter the epithelial cell 
either through passive diffusion or through fatty acid transport proteins. MGAT catalyzes the reaction that 
forms DAG from MAG and a free acyl-CoA. DGAT catalyzes the reaction that forms TAG. The PCTV, 
composed of TAG, proteins, and cholesterol, matures in the Golgi, exits the epithelial cell through the 
basolateral membrane, and enters the lymphatic system.  
Once inside the tissue, fatty acids can either be re-esterified and stored in the form of 
triglycerides or they can be oxidized. Short and medium chain fatty acids that are eight carbon 
units in length or smaller are able to diffuse directly through the mitochondrial membrane into the 
matrix where they are activated by CoA. On the other hand, long-chain acyl-CoA synthetase 
(ACS) is required to activate long chain fatty acids and they are subsequently transported into the 
mitochondrion through the use of the carnitine shuttle51. Along the outer mitochondrial membrane, 
carnitine palmitoyltransferase 1 (CPT1) catalyzes the rate limiting reaction in which a fatty acyl 
CoA is carnitinized to yield a fatty acyl carnitine. Once formed, the fatty acyl carnitine is able to 
cross the inner mitochondrial membrane through the help of carnitine–acyl carnitine translocase 
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(CACT)52. Inside the matrix, CPT2 catalyzes a reaction in which the acyl chain is transferred from 
carnitine to CoA in order to commence β-oxidation. Meanwhile, carnitine is free to diffuse back 
into the intermembrane space. β-oxidation is a cycle that leads to shortening of acyl-CoAs through 
the repetitive cleavage of 2-carbon acetyl-CoA units. It begins with very long chain acyl-CoA 
dehydrogenase (VLCAD) striping a hydrogen atom from the second and third carbons thereby 
creating trans-2-enoyl-CoA and FADH2 in the process. The mitochondrial trifunctional protein 
(MTP), which has hydratase, dehydrogenase, and thiolase activity, carries out the ensuing three 
reactions53. MTP adds H20 which breaks the double bond and adds a hydroxyl group to the third 
carbon, creating 3-hydroxyacyl-CoA. Then, a dehydrogenation reaction occurs in which NADH 
and β-ketoacyl CoA are formed. Subsequently, an acetyl-CoA unit is cleaved on the β carbon from 
the carboxyl end through MTP’s thiolase activity. The existing acyl chain re-enters the cycle in 
order for β-oxidation to proceed. Each acetyl-CoA that emerges from this cycle can then enter the 
citric acid cycle and form ATP through the electron transport chain. 
 
Figure 2: Long chain fatty acid transport into mitochondria and β-oxidation. Long chain fatty acids are 
activated with CoA prior to entering the mitochondrion. They bind to carnitine in order to enter the matrix. 
Subsequently, the fatty acids dissociate from the carnitine shuttle and proceed with β-oxidation.  
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Fatty acid synthesis 
Elongation 
In order to appreciate the significance of why ω-3 fatty acids are considered to be essential, 
there needs to be a thorough understanding of fatty acid synthesis. Within mammalian de novo 
lipogenesis, the carbon source can originate from carbohydrates and proteins. Amino acids can 
enter the cellular respiration pathway at various stages. However, glucose enters in the first step 
of glycolysis, which occurs in the cytosol. Pyruvate, the product of glycolysis, enters the 
mitochondrion, where pyruvate dehydrogenase produces acetyl CoA. These acetyl CoA units must 
be transferred from the mitochondrion back to the cytosol, where de novo lipogenesis takes place. 
To accomplish this, acetyl-CoA enters the Krebs cycle and combines with oxaloacetate to produce 
citrate, a molecule that is able to cross the mitochondrial membrane54. The tricarboxylate transport 
system facilitates the crossing of the membrane. Once in the cytosol, citrate is converted back into 
acetyl CoA by ATP citrate lyase and is now ready for fatty acid biosynthesis. Meanwhile, 
oxaloacetate can be converted to malate and then pyruvate which can then re-enter into the 
mitochondrion. Once acetyl-CoA is in the cytoplasm, acetyl-CoA carboxylase (ACC) adds a 
carboxyl group to create malonyl CoA. Acetyl CoAs and malonyl CoAs are stripped of their CoA 
components and are both transferred to acyl-transfer proteins (ACP) through the activity of 
malonyl-acetyl transferase54. Acetyl ACP and malonyl ACP undergo a condensation reaction 
which creates 3-ketoacetoacyl ACP and releases CO2 in the process. A reduction reaction follows 
in which NADPH (from pentose phosphate pathway) is oxidized to NADP and facilitates the 
creation of 3-hydroxyacyl ACP. This compound is then dehydrated in order to create enoyl ACP 
which has a double bond between the second and third carbons54. Enoyl ACP is reduced once 
again to create butyryl ACP, a saturated 4-carbon unit. This cycle is then repeated until palmitic 
acid, a saturated 16-carbon fatty acid, is formed (Figure 3). Although the location of fatty acid 
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elongation beyond this point is shifted to the endoplasmic reticulum membrane, the process 
remains similar to the one described above. With the addition of one more malonyl CoA, stearic 
acid, an 18-carbon saturated fatty acid, is formed. This reaction and all subsequent elongations are 
catalyzed by elongation of very long chain fatty acids (ELOVL) enzymes. There are seven ELOVL 
proteins all of which vary in expression depending on the tissue and have different affinities for 
fatty acids depending on saturation level54. 
 Desaturation 
Mammalian cells have Δ5, Δ6, and Δ9-desaturase capabilities. Each number refers to the 
carbon, counting from the carboxyl end, where the enzyme can form a double bond55. Continuing 
from stearic acid, Δ9-desaturase is able to form oleic acid, a monounsaturated fat that is the major 
component of olive oil56. A Δ12-desaturase is required to create linoleic acid, a polyunsaturated 
ω-6 fatty acid. Due to the fact that mammals lack the desaturase required to form this fatty acid, it 
is termed essential. The name, ω-6 comes from the fact that the first double bond counting from 
the methyl end occurs on the 6th carbon. Furthermore, a Δ15-desaturase is required in order to 
convert linoleic acid to α-linolenic acid (ALA), an ω-3 fatty acid. This desaturase is only present 
in plants which makes ALA an essential fatty acid as well. Once present in the body, ALA can 
undergo Δ6-desaturation, followed by a series of elongations and desaturations resulting in the 
creation of EPA and then DHA the two ω-3 fatty acids that have the greatest bioavailability and 
therapeutic potential. In theory, ALA is the only essential ω-3 fatty acid because humans have the 
desaturases necessary to produce the rest. However, the rate limiting step is Δ6-desaturation of 
ALA since linoleic acid competes for access to this enzyme (Figure 3). This results in less than 
10% of ALA being converted to DHA in females and less than 3% in males. Thus, in practical 
terms, due to the inefficiency of their conversions, both EPA and DHA are necessary to obtain 
from the diet57.  
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Figure 3: Fatty acid synthesis pathway. Repetitive addition of malonyl CoA yields palmitate, a saturated 
16-carbon fatty acid. Absence of Δ12 and Δ15 desaturases in humans means that linoleic and α-linoleic 
acid are both essential. Competition for Δ6-desaturase leads to low quantities of EPA and DHA.  
 
Sources of omega-3 fatty acids 
It is thought that prior to the agricultural revolution, hominid diet consisted largely of 
seafood which yielded an ω-6: ω-3 ratio of approximately one58. Thus, from an evolutionary 
prospective, it would not have been any more advantageous to be able to synthesize ω-3 fatty acids. 
However, with a typical present-day western diet, the ratio of ω-6 to ω-3 is around 20:1. In the last 
20 years, the ratio of ω-6 to ω-3 has also increased in breast milk which has played a role in the 
rising rates of childhood obesity59. -6 fatty acids promote the production of pro-inflammatory 
mediators and are contributors to the increased prevalence of conditions that are characterized by 
chronic inflammation. Thus, it is imperative to have an adequate amount serum and tissue ω-3 
fatty acid content to help counteract the negative effects of ω-6 fatty acids. The abundance of ω-3 
fatty acids in adipose tissue, the main storage site for fatty acids, is relatively small. ALA is the 
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major ω-3 fatty acid stored in this tissue and it accounts for approximately 1% of all fatty acids60. 
Thus, EPA and DHA are stored in limited quantities and are therefore required to be consumed 
consistently through the diet. There are a variety of sources from which one can obtain ω-3 fatty 
acids such as seeds, vegetables, oils, fish, and supplements. For instance, chia seeds, hemps seeds, 
and flaxseed oil are all excellent sources of ALA with 17.8g, 8.7g, and 53.4g respectively of ALA 
per 100g59. However, as mentioned earlier, the bioavailability of ALA is relatively limited, and 
instead, sources of EPA and DHA should be sought. It is also important to note that in nature, 
polyunsaturated fatty acids do not exist in isolation, but rather a mixture of ω-3, ω-6, 
monounsaturated, and/or saturated fatty acids and their relative proportions can vary overtime. For 
example, the average avocado has 13.3g of monounsaturated fat, 2.5g of polyunsaturated fat, and 
2.9g of saturated fat. As the avocado ripens, its saturated fat content slightly decreases, while its 
monounsaturated fat increases slightly61. Phytoplankton are the main source of ω-3 fatty acids in 
the aquatic environment. As a consequence, fish and crustaceans such as krill that consume 
phytoplankton are rich in ω-3 fatty acids. Fish can be categorized based on their relative fat content 
as well as the distribution of lipids within their various tissues. Lean fish such as bass, cod, and 
catfish have relatively little fat and use their liver as the predominant lipid storage area. However, 
fatty fish such as salmon, herring, and mackerel are lipid rich and have a higher percentage of 
lipids stored within their muscle and skin tissue62,63. Fatty fish as well as the liver of lean fish are 
excellent sources of essential polyunsaturated fatty acids and are recommended to consume for 
this reason. Each fish has a different proportion of polyunsaturated fatty acids based on their 
environmental conditions. Wild sources of fish have higher ω-3 fatty acid content than their farmed 
counterparts. This is because wild fish feed on phytoplankton as opposed to the cereal-based 
formula that farmed fish eat. Furthermore, fish that come from cold water as opposed to warm 
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water environments have a higher proportion of long chain polyunsaturated fatty acids59. However, 
fish can accumulate contaminants such as mercury which has a half life of 70-90 days and heavy 
consumers of fish can suffer the consequences of toxicity64. To minimize the risk of toxicity and 
still benefit from the ω-3 fatty acids present in fish, the European Food Safety Agency, the 
American Heart Association, and the World Health Organization all recommend approximately 1-
2 servings of fatty fish a week65.  Furthermore, the commercialized extraction of oil from marine 
organisms has provided an alternative source of ω-3 for humans. Fish oil supplements reflect the 
diversity in fatty acid makeup among fish in nature. There are a variety of options to choose from 
such as krill oil, cod liver oil, and algal oil. Krill oil is considered to have a higher bioavailability 
than other fish oils because it has 35% of its DHA in the form of phospholipids which are easier 
to integrate as opposed to triglycerides66. Overconsumption of fish oil supplements can also 
increase the risk of lipid peroxidation which can damage muscle, nerves, and membranes. To 
mitigate this risk, it is necessary to consume adequate levels of vitamin E and regulate the 
frequency of fish oil supplement consumption64.  
Mechanism of action 
On a cellular level, fatty acids are central components of the phospholipid bilayer that 
forms the foundation of all cell membranes. Phosphatidylethanolamine, phosphatidylserine, 
sphingomyelin, and phosphatidylcholine are the four most common phospholipids found in animal 
membranes67. The phospholipids in the inner leaflet are arranged with their polar heads directed 
towards the cytosol, while those in the outer leaflet have their polar heads pointed towards the 
extracellular matrix. The two layers of phospholipids have their non-polar fatty acid chains facing 
each other which creates a hydrophobic interior. Incorporation of ω-3 fatty acids into a cell 
membrane can increase the fluidity of the cell membrane due to the kinks that are created by the 
double bonds present in the structure of the fatty acid68. Membrane fluidity can enhance the 
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permeability to molecules of smaller size thereby altering the plasma membrane environment69. 
This increased fluidity can also alter the function of channels, receptors and membrane processes 
as a whole70,71. Proteins that require mobility within the membrane are especially dependent on 
membrane fluidity and are thus indirectly affected by the presence of polyunsaturated fatty acids. 
-3 fatty acids can also have a direct effect on the activity of receptors and integral membrane 
proteins by restricting conformational changes and associating with hydrophobic regions of 
proteins72. Moreover, higher quantities of polyunsaturated fatty acids in membranes have been 
associated with greater proportion of insulin receptors73,74. This provides further evidence for the 
role that ω-3 fatty acids have in altering the plasma membrane lipid environment and altering cell 
function. 
Within the phospholipid bilayer, ω-3 fatty acids can integrate into lipid rafts and alter their 
composition and function. Lipid rafts are components of the cell membrane that are generally 
composed of glycosphingolipids and cholesterol75. Various regulatory membrane proteins 
routinely assimilate into lipid rafts, which presents these rafts with cell signalling properties76. 
Stulnig et al. demonstrated that human T-cells treated with polyunsaturated fatty acids had a 
significantly greater proportion of unsaturated acyl chains within the lipid raft than untreated cells, 
which altered the fate of critical signalling proteins77. Therefore, ω-3 fatty acids can influence cell 
signalling indirectly by integrating into lipid rafts and modulating their lipid composition.  
The various phospholipids that form the basis of the plasma membrane can be used as 
substrates by phospholipases for the production of second messengers that are involved in various 
signalling pathways. For instance, the second messengers diacylglycerol (DAG) and inositol 
triphosphate (IP3) are produced from the phospholipids, phosphatidylinositol bisphosphate, and 
phosphatidyl-choline. In addition, protein kinase C (PKC), an enzyme that is involved in cell 
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signalling, requires phosphatidylserine for its activation and certain isoforms of PKC are also 
activated by DAG78. Kishimoto et al. have shown that DAGs that contain unsaturated fatty acid 
moieties, such as diarachidonoylglycerol and dioleoylglycerol, are better able to activate PKC than 
DAGs containing saturated fatty acids79. Therefore, the activity of certain enzymes and their 
products are highly dependent on the type of phospholipid and its constituent fatty acid78.  
Membrane phospholipids can also be cleaved by phospholipases for alternative fates. -3 fatty 
acids can be used by cyclooxygenase (COX) and lipoxygenase (LOX) enzymes to synthesize 
eicosanoids such as prostaglandins, thromboxanes, lipoxins, and leukotrienes80. Eicosanoids 
facilitate the inflammatory response, however the fatty acid precursor that is used as the substrate 
in eicosanoid production dictates the intensity and the physiological role of the eicosanoid. -3 
fatty acids in the phospholipid bilayer would compete with and lower the amount of arachidonic 
acid, an ω-6 fatty acid, incorporated into membrane phospholipids. Consequently, there is less 
arachidonic acid substrate available for eicosanoid synthesis. The eicosanoids that are produced 
from ω-3 fatty acids have different structures and functions from those produced by arachidonic 
acid, with the former having a bioactivity that is less efficient than the latter. The leukotriene 
originating from ω-3 fatty acids is up to 100 times less potent of an attractant to neutrophils than 
leukotrienes originating from ω-6 fatty acids81. Wada et al. also demonstrated that ω-3-derived 
prostaglandins were 50-80% less potent than their ω-6 counterparts towards the eicosanoid 
receptors82. Therefore, ω-3 fatty acids can not only act as second messengers that regulate 
signalling pathways, but can also dampen the inflammatory response by mediating eicosanoid 
synthesis.   
Within the cell membrane, there are four types of transmembrane G-protein coupled 
receptors that bind fatty acids, with GPR40 and GPR120 binding long chain fatty acids83,84. These 
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receptors trigger intracellular signalling pathways that can produce anti-inflammatory and 
metabolic responses. Once EPA and DHA bind to and activate GPR120, the B-arrestin 2 protein 
is recruited to the plasma membrane where it forms a complex with GPR120. This complex then 
penetrates the cytoplasm and binds to the transforming growth factor-β-activated kinase 1 (TAK1)-
binding protein. As a result, the TAK1-binding protein’s ability to interact with TAK1 is hindered 
which reduces the activation of TAK1 and consequently the NF-κB signalling pathway81. Through 
the decreased phosphorylation of the inhibitory subunit, IkB, the NF-κB complex is no longer able 
to translocate to the nucleus to transcribe inflammatory cytokines85. The TNF receptor and the 
TLR4 inflammatory signalling pathway are dependent on the binding of TAK1 to TAK1-binding 
protein as well. This means that ω-3 fatty acids can suppress the expression of pro-inflammatory 
genes like TNFα and IL-6, but also interrupts the signalling of TLR4 and NF-κB signalling 
pathways81. Through the activation of GPR120, DHA has been shown to be able to stimulate 
GLUT4 translocation to the surface of adipocyte cells and consequently promote glucose uptake. 
In fact, 30 min of exposure to DHA (100 μM) increased basal glucose uptake by ~2-fold, which 
was equivalent to 30-50% of the insulin-stimulated glucose uptake response in 3T3L1 
adipocytes16. Therefore, by binding to G-protein coupled receptors, ω-3 fatty acids can exert anti-
inflammatory effects and alter uptake and metabolism of glucose in cells.  
-3 fatty acids along with their eicosanoid products are able to act as ligands for 
peroxisome proliferator-activated receptors (PPAR), which have various isoforms (α, δ and γ). 
Upon binding to their ligands, PPARs translocate to the nucleus where they associate with the 
retinoid X receptor and trigger the transcription of genes86. PPARα is highly expressed in skeletal 
muscle and is responsible for regulating β-oxidation and lipid homeostasis. For instance, activation 
of PPARα in skeletal muscle has been shown to enhance lipid oxidation and increase the 
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expression of carnitine palmitoyltransferase I (CPT-1), a rate limiting enzyme of β-oxidation of 
long-chain fatty acids87. At a tissue-specific level, muscle can display impairment in insulin-
stimulated glucose uptake due to impaired ability to oxidize fat and lipid accumulation88,89. 
Therefore, the ability of ω-3 fatty acids to enhance fat oxidation in muscle tissue through PPARα 
activation can reduce insulin resistance and improve glucose utilization90. With regard to the other 
PPAR isoforms, it has been demonstrated that there is a functional overlap between PPARδ and 
PPARα91. Indeed, an increase in fatty acid uptake and oxidation was found when L6 skeletal 
muscle cells were treated with PPARδ agonists92. PPARδ is also implicated in peroxisome 
proliferator-activated receptor gamma coactivator 1-alpha (PGC1-α) upregulation and 
mitochondrial biogenesis, which is consistent with improved cellular oxidative capacity93–96. The 
activation of PPARγ, despite having an expression in muscle that is 5-10% of its expression in 
adipose tissue, has a significant role in muscle insulin sensitivity97,98. In fact, pioglitazone, a 
PPARγ agonist has been shown to ameliorate insulin sensitivity of an in vivo type II diabetic 
model99. Deletion of PPARγ in skeletal muscle has led to extreme glucose intolerance and insulin 
resistance in mice100. In addition, when PPARγ is activated, it can physically interfere with the 
translocation of NF-κB to the nucleus, which provides an alternative mechanism of shutting down 
the NF-κB inflammatory pathway80. Thus, ω-3 fatty acids can potentially influence skeletal muscle 
energy metabolism through multiple mechanisms.  
In the context of cellular energetics, EPA and DHA can serve as agonists of AMP-activated 
protein kinase (AMPK). AMPK is an important protein that regulates mitochondrial biogenesis 
and oxidative capacity through the activation of PGC1-α and nuclear respiratory factors101. AMPK 
also acutely influences fatty acid oxidation through the phosphorylation and inactivation of acetyl 
CoA carboxylase (ACC), which limits the production of the CPT-1 inhibitor malonyl CoA102. 
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Activation of AMPK can facilitate the translocation of GLUT4 to the plasma membrane and 
increase skeletal muscle glucose uptake103,104. Furthermore, AMPK can upregulate the expression 
of PPARγ in skeletal muscle, which demonstrates the diverse functions of this protein105. Aside 
from AMPK activation, rats fed a diet high in polyunsaturated fatty acids have been shown to 
increase the number of insulin receptors as well as the expression of GLUT4 and IRS1 receptors 
in skeletal muscle106,107. Therefore, ω-3 fatty acids can potentially play an insulin sensitizing role 
and promote glucose uptake and its metabolism. In this context, the AKT protein, which is central 
to the insulin signalling pathway, is of particular interest. The ability of ω-3 fatty acids to modulate 
this pathway has been demonstrated in neuroblastoma cells in mice, epithelial cells of human lung 
carcinoma, and human pancreatic epithelial cells108–110. The phosphorylation of AKT would lead 
to a cascade of intracellular events that promote GLUT4 translocation, phosphorylation/inhibition 
of glycogen synthase kinase 3 (GSK3), and enhanced activity of glycogen synthase (GS).  
Rodent and human studies exploring the effects of ω-3 fatty acids 
In the 1950s and 1960s it became apparent that Alaskan natives have much lower rates of 
insulin resistance, type-2 diabetes, and metabolic syndrome than the general population111. Here, 
the authors of the study ruled out any influence of diet on these findings. However, subsequent 
studies analyzed data collected from the Alaska Siberia Project in order to specifically determine 
whether there was a link between plasma polyunsaturated fatty acid concentrations and the 
prevalence of metabolic syndrome. Three hundred and fifteen Eskimos between the age of 35 and 
74 who lived in 4 different villages in Northern Alaska were used for this study. Their results show 
that ω-3 fatty acids are related to higher levels of plasma HDL concentration and lower levels of 
fasting insulin, triglyceride concentrations and 2-hour blood glucose112. Several other studies have 
documented that populations with high fish consumption have a lower incidence of type-2 
diabetes. In this context, Helland et al. investigated the whether the type of fish is a factor. To 
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conduct the study, 76 overweight or obese adults ranging from 18 to 69 years old were recruited 
to either consume 750g per week of cod (lean fish) or salmon (fatty fish) for eight weeks. A third 
group ate no fish and served as the control. Their results show that the fatty fish group, but not the 
lean fish group, had lowered their postprandial glucose and insulin concentrations which are 
indicative of improved insulin sensitivity and glucose tolerance. They also measured leukocyte 
membrane fatty acid composition and determined that fatty fish consumption leads to lower ω-6 
and higher ω-3 fatty acid membrane composition. This means that ω-6-derived eicosanoids would 
decrease while augmenting the production of resolvins and protectins, and ω-3-derived anti-
inflammatory eicosanoids. In a study by Lalia et al., 7 female and 5 male adults between the ages 
of 65 and 85 were evaluated at baseline and after 16 weeks of daily ω-3 fatty acid supplementation 
of 3.9g. Although mitochondrial respiration levels remained the same, there was a 25% decrease 
in reactive oxygen specie production. This study demonstrates the potential for ω-3 fatty acids to 
limit the release of oxidants and therefore ameliorate mitochondrial function113. However, many 
human studies provide findings that are contrary to this. For instance, among 4941 participants 
from the National Heart, Lung, and Blood Institute Family Heart Study, of which 21% had 
metabolic syndrome, neither ω-3 fatty acids nor fish consumption was associated with metabolic 
syndrome114. Another study showed that in 8 patients with impaired glucose tolerance, 3.8g of 
EPA and 2.5g of DHA added to their regular diet daily for 2 weeks led to no changes in fasting 
glucose and insulin concentrations115. Similarly, as compared to those receiving placebo, insulin-
resistant adults who received a 3.9g EPA + DHA mixture for 6 months showed no measurable 
improvement in peripheral glucose disposal or skeletal muscle mitochondrial function116. Thus, 
human studies have been generally equivocal; however, rodent studies have been more conclusive 
in demonstrating the therapeutic value of ω-3 fatty acids in insulin resistant states. Indeed, fat-1 
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transgenic mice, capable of synthesizing -3 fatty acids from -6 fatty acids, demonstrate 
improved whole-body glucose tolerance when compared to wild-type mice117. In another study, 
Bidu et al. wanted to test whether the transplantation of a microbiome that was altered due to 
elevated ω-3 fatty acid concentrations could mitigate the deleterious effects of a high sucrose high 
fat diet. For this study, they used fat-1 transgenic mice which effectively balanced the ratio of ω-
6 to ω-3. The fat-1 mice exhibited increased cecal microbiome diversity, reduced endotoxemia, 
and preserved intestinal integrity that is usually broken down with a high fat diet. In addition, 
transplantation led to the reversal of metabolic dysfunction brought on by a high sucrose high fat 
diet in wild type mice118. Here, it is evident that ω-3 fatty acids have broad and potent effects on 
multiple tissues throughout the body. However, in these transgenic mice, it is challenging to 
identify the specific effects of -3 fatty acids, due to the simultaneous fluctuation in -6 fatty acid 
concentration. For this reason, Lamping KG et al. induced obesity in mice through a 12 week HF 
diet and subsequently replaced half of the calories with monounsaturated, ω-3, or ω-6 fatty acids. 
The mice that were fed ω-3 fats were better able, as compared to mice who were fed 
monounsaturated or ω-6 fatty acids, to ameliorate glucose tolerance and AKT phosphorylation in 
skeletal muscle tissue119. Similarly, rats fed a high fat fish oil-based diet as opposed to a standard 
HF diet, showed greater insulin sensitivity and lower systemic inflammation and adipocyte 
diameter106. In cultured adipocytes, EPA was actually able to stimulate AMPK phosphorylation 
and could potentially improve insulin insensitivity through this mechanism120. In a separate study, 
obese rats who consumed a HF diet supplemented with 10% v/w ω-3 fish oil, led to an increase in 
AMPK-α1 gene expression in the soleus muscle. This was complemented with a reduction in 
serum free fatty acids, triglycerides, total cholesterol, and glucose levels. Evidently, there is a 
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plethora of studies that have provided support for the therapeutic value that ω-3 fatty acids can 
have for insulin resistance. 
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Objectives and hypothesis 
-3 fatty acids are known for their anti-inflammatory properties and as a result have been 
associated with beneficial outcomes for conditions that are characterized by chronic inflammation 
such as type-2 diabetes, insulin resistance, and metabolic syndrome. Due to the fact that skeletal 
muscle tissue accounts for ~40% of body weight in men and ~30% in women and is responsible 
for ~80% of post-prandial glucose disposal, it likely plays an important role in this response. 
However, it was unclear whether ω-3 fatty acids exert their effects on skeletal muscle tissue 
through a reduction in inflammation or through the direct regulation of energy metabolism. Thus, 
the objective of this study was to investigate whether docosahexaenoic (DHA) and 
eicosapentaenoic (EPA) acids can directly regulate glucose and fat metabolism in L6 rat skeletal 
muscle cells, independent of their anti-inflammatory properties. In this context, we hypothesized 
that besides exerting an anti-inflammatory effect, ω-3 fatty acids could indeed improve glucose 
and fat metabolism in skeletal muscle cells through their direct regulation of proteins that underlie 
these pathways. 
Also, because EPA and DHA segregate differently between raft and non-raft cell 
membrane domains121 and seem to distinctly regulate skeletal muscle mitochondrial oxidative 
capacity122, we tested these fatty acids individually. We exposed L6 skeletal muscle cells to either 
EPA or DHA for 1, 3, and 5 days and then assessed several parameters of glucose and fatty acid 
metabolism along with the phosphorylation and content of various proteins that underlie these 
processes. Lastly, mRNA was extracted to assess the expression of various genes implicated in 
inflammation.  
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Abstract 
 The objective of this study was to investigate whether docosahexaenoic (DHA) and 
eicosapentaenoic (EPA) acids can directly regulate glucose and fat metabolism in skeletal muscle, 
besides exerting anti-inflammatory properties. To accomplish this, L6 skeletal muscle cells were 
treated with 50µM of either DHA or EPA for 1, 3, and 5 days. Subsequently, we assessed glucose 
uptake, glycogen synthesis, lactate production, glucose and palmitate oxidation, as well as the 
phosphorylation and contents of proteins involved in insulin signalling and regulation of cellular 
oxidative capacity. mRNA expression of several genes involved in inflammation was also 
measured after DHA or EPA treatment. We found that basal rates of glucose uptake and glycogen 
synthesis as well as protein kinase B (AKT) and glycogen synthase kinase 3 (GSK3) 
phosphorylation remained unaffected by DHA or EPA. In addition, similar findings were observed 
under insulin-stimulated conditions. However, glucose and palmitate oxidation rates were 
consistently increased (day 1 to 5) by DHA treatment, whereas EPA only increased this variable 
transiently (day 1). Similarly, only DHA caused significant and sustained increases in AMP-
activated protein kinase (AMPK) phosphorylation and contents of carnitine-palmitoyl transferase 
1b (CPT1b) and peroxisome proliferator-activated receptor gamma coactivator 1α (PGC-1α) in 
skeletal muscle cells. DHA also had a more potent anti-inflammatory effect than EPA in these 
cells. In conclusion, besides exerting anti-inflammatory effects, DHA and EPA directly regulated 
glucose and fat metabolism in skeletal muscle cells, although DHA was more potent in doing so 
than EPA. Thus, by directly enhancing glucose and fat oxidation, DHA may increase glucose 
disposal and protect skeletal muscle cells against lipotoxicity.   
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Introduction 
-3 fatty acids are well known for their anti-inflammatory properties and therapeutic value 
for conditions that are characterized by chronic inflammation2,4. With the rise in the global 
prevalence of obesity and its related metabolic disorders, there has been great focus on the potential 
role that -3 fatty acids can play in ameliorating the inflammation-induced metabolic disorders 
that often accompany obesity. Indeed, there are reports that intake of -3 fatty acids improves 
glucose tolerance in healthy humans and in those with metabolic syndrome5–8. To identify the 
specific effects of -3 fatty acids, mice consuming a high-fat (HF) diet had 7.5% of their calories 
replaced with fish oil. The dysfunctional metabolic alterations in skeletal muscle caused by a HF 
diet were reversed in fish oil-fed mice, in part by facilitating the upregulation of proteins involved 
in lipolysis and lipid oxidation in this tissue9. Also, rats fed a HF diet with 3.4% of calories coming 
from eicosapentaenoic and docosahexaenoic acids (EPA and DHA, respectively) had lower blood 
glucose and higher skeletal muscle expressions of GLUT4, GYS1, and IRS1 than rats fed a regular 
HF diet10. Based on animal studies, it is evident that -3 fatty acids can beneficially affect whole-
body glycemic control, and they appear to do so, at least in part, through their regulation of glucose 
and fat metabolism in skeletal muscle cells. However, human studies have not consistently 
recapitulated rodent findings, so the validity of supplementing -3 fatty acids for improvement in 
glycemic control in humans remains a contentious topic123. 
With respect to the etiology of insulin resistance, it has been proposed that the excessive 
intramyocellular accumulation of triglycerides (TAG) and diacylglycerols (DAG) leads to the 
disruption of insulin signaling in skeletal muscle cells. This is based on the observation that DAG 
can activate protein kinase C (PKC), which, in turn, phosphorylates serine residues on IRS-1 and 
impairs the ability of insulin to induce phosphorylation of tyrosine residues on this protein13,124. 
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Thus, it has been suggested that suppressing the accumulation of harmful lipid intermediates 
through the enhancement of fatty acid oxidation within skeletal muscle cells may prevent insulin 
resistance in this tissue. Consistent with this idea are reports that fish oil supplementation is 
associated with a reduced accumulation of lipid mediators such as ceramides and long chain acyl-
CoAs in skeletal muscle tissue of mice fed a HF diet10. Whether these effects derive from -3 fatty 
acids directly regulating the ability of skeletal muscle cells to uptake and metabolize fatty acids or 
indirectly through their anti-inflammatory properties remains undetermined. However, ω-3 fatty 
acids display unique chemical and physical properties that can affect membrane fluidity and cell 
function. For instance, DHA is a highly flexible molecule that can rapidly transition between 
numerous conformers with the ability to enter binding pockets of proteins and also act as ligands 
for receptor proteins125. In addition, ω-3 fatty acids can be incorporated into cell membranes and 
form lipid rafts, which could then interact with specific proteins and regulate downstream signaling 
pathways121,126, as well as modulate the expression of genes related to mitochondrial biogenesis, 
oxidative capacity, and cellular energy supply122. In this context, we hypothesized that besides 
exerting anti-inflammatory properties, ω-3 fatty acids could directly regulate glucose and fat 
metabolism in skeletal muscle cells. Also, because EPA and DHA segregate differently between 
raft and non-raft cell membrane domains121 and seem to distinctly regulate skeletal muscle 
mitochondrial oxidative capacity122, we tested these fatty acids individually. We exposed L6 
skeletal muscle cells to either EPA or DHA for 1, 3, and 5 days and then assessed several 
parameters of glucose and fatty acid metabolism along with the phosphorylation and content of 
various proteins involved in these processes. Lastly, mRNA was extracted to assess the expression 
of various genes implicated in inflammation. Here, we show that DHA, and EPA can directly affect 
glucose and fat oxidation in skeletal muscle cells. However, DHA was the most consistent in doing 
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so. Furthermore, these effects were accompanied by sustained elevations in AMPK 
phosphorylation and CPT1b and PGC-1α contents. DHA treatment also consistently reduced the 
mRNA expression of genes involved in inflammation, whereas EPA only exerted transient effects. 
Therefore, DHA seems to be more effective than EPA in directly enhancing glucose and fat 
oxidation in skeletal muscle cells, as well as in simultaneously attenuating the ability of these cells 
to respond to inflammatory mediators. 
 
Methods 
Chemicals and reagents – Antibiotic-antimycotic (Cat # 450-115-EL), α-minimal essential 
medium (α-MEM) with (Cat # 310-010-CL) and without phenol red (Cat # 310-015-CL), Fetal 
Bovine Serum (FBS) (Cat # 080-150), trypsin (Cat # 325-040-EL), Phosphate Buffered Saline 
(PBS) (311-010-CL), were purchased from Wisent Bioproducts (St-Bruno, Quebec, Canada). 
Fatty acid-free BSA (Cat # A3803) was purchased from Sigma-Aldrich (St. Louis, MO). DHA 
(Cat# 90310), EPA (Cat # 90110), and α-tocopherol (Cat # 25985) were purchased from Cayman 
Chemical (Ann Arbour, MI). Protease inhibitor cocktail (Cat # 5892953001) and phosphatase 
PhosphoStop inhibitor cocktail (Cat # 4906837001) were from Roche Diagnostics (Mannheim, 
Germany). 2x Laemmli Sample Buffer (Cat # 1610737) was bought from Bio Rad (Mississauga, 
ON, Canada) and Immobilon Forte Western HRP Substrate (Cat # WBLUF) was purchased from 
Millipore (Billerica, MA). 2-deoxy-D-[H3] glucose was purchased from Perkin Elmer (Seer Green, 
United Kingdom), [1-14C] palmitic acid was from American Radiolabeled Chemicals (St. Louis, 
MO) and d-[U-14C] glucose was from GE Healthcare Radiochemicals (Quebec City, QC, Canada). 
Regular human insulin was bought from Eli Lilly (Indianapolis, IN). The lactate colorimetric assay 
kit (Cat# K607-100) was purchased from BioVision (San Francisco, CA) and the CellTiter-Glo® 
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Luminescent Cell Viability Assay (Cat # G7570) was from Promega (Madison, WI). TRIzolTM 
Reagent (Cat # 15596026) was bought from ThermoFisher Scientific (Waltham, MA). 
EasyScriptTM cDNA Synthesis Kit (Cat # G491) and BrightGreen 2X qPCR Mastermix (Cat # 
Mastermix-S) was obtained from ABM (Richmond, BC, Canada). All antibodies were purchased 
from Cell Signaling (Danvers, MA), other than PGC-1α which was obtained from Millipore 
(Billerica, MA) and CPT1b that was bought from Bosterbio (Pleasanton, CA).  
Complexation of EPA and DHA with BSA – DHA and EPA stock solutions (10 mM) were 
prepared after complexation of each fatty acid with fat-free BSA (12.5%, w/v) in α-MEM. Two 
separate solutions containing fat-free BSA either with EPA or DHA were incubated overnight in 
a shaking water bath at 50 oC. Subsequently, each solution was filtered and an aliquot was collected 
to measure fatty acid concentration using the Wako NEFA kit. α-tocopherol (40 μM) was added 
to the mixture to prevent lipid peroxidation and the final solution was split into aliquots to be stored 
at -20 oC.  
Cell culture and treatment – Rat L6 skeletal muscle cells (American Type Culture Collection) 
were grown in α-MEM containing FBS (10%, v/v) and 1% (v/v) antibiotic-antimycotic solution. 
Cells were grown in a humidified environment that was maintained at 37°C and 5%   2 as 
previously described127. Cell growth was conducted in T75 flasks while maintaining confluence 
levels of approximately 80%. Cells for all treatment conditions were seeded onto a plate/dish at 
the same time and placed in the 37°C incubator. Wells that contain the 5-day treatment condition 
were treated first, then 2 days later the 3-day treatment condition was added, and two days later 
the 1-day treatment condition was performed. Thus, the cells were treated with either EPA, DHA 
or control media for 1, 3, or 5 days. The assays were conducted immediately after day 5 of 
treatment with all cells equally aged. Previous studies have shown that a 50 μM ω-3 fatty acid 
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concentration would maintain cell viability while still being representative of a serum ω-3 
concentration which consequently informed our decision to use this concentration for our 
study17,128–131.  
Measurement of glucose uptake – Cells were seeded into 24-well plates, treated for 1, 3, and 5 
days, and on the day of the experiment, cells were serum starved for 4h. This means that they were 
exposed to α-MEM containing 1% (v/v) antibiotic-antimycotic, but without FBS. Half of the cells 
were treated with 100 nM insulin for 30 min after which all the plates were removed from the 37°C 
incubator and washed with a Hepes-buffered saline (HBS) solution (20 mM Hepes-Na, 1 mM 
CaCl2, 2.5 mM MgSO4, 140 mM NaCl and 5 mM KCl, pH 7.4). As previously described, a solution 
containing 10 μM 2-deoxy-D-glucose and 0.5 μCi/ml of radiolabelled 2-deoxy-D-[3H] glucose 
dissolved in HBS was given to the cells132. To account for non-specific background radioactivity, 
200 µl of the existing radiolabelled solution containing 10 µl of cytochalasin B (10 μM) was given 
to one well in each plate. Cells were then incubated at room temperature for 5 min and then 
immediately placed on ice. The incubation media was quickly aspirated and then the cells were 
washed with cold 0.9% saline twice. A lysis solution (0.05 M NaOH) was then added to every well 
and the plate was placed on a shaker for 15 min to lyse the cells. The cell lysates that formed were 
placed in scintillation vials for radioactivity counting. A 10 µl aliquot of the lysate was used to 
determine protein concentrations using the Bradford assay.  
Measurement of glucose and palmitate oxidation – Cells were seeded into 35x10 mm dishes, 
treated for 1, 3, and 5 days, and on the day of the experiment they were serum starved for 4h. All 
wells were then aspirated and given different solutions depending on the assay. To measure 
glucose oxidation, cells were given α-MEM containing 0.1 µCi/ml radiolabelled D-[14C] glucose 
as previously described133. For palmitate oxidation, cells were given α-MEM containing 20 μM 
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palmitate as well as 0.15 µCi/ml radiolabelled [1-14C] palmitic acid. For both assays, dishes were 
air-sealed using parafilm, while a piece of Whatman paper is attached on the inside and placed in 
the 37°C incubator for 1h. Afterwards, 200 µl of 4 M H2SO4 was applied to the cells and 100 µl 
of a phenylethylamine-methanol (1:1) mixture was applied to the Whatman paper. The dishes were 
then placed back into the 37°C incubator for 1h to collect 14CO2 released by the cells. The 
Whatman papers were then carefully removed from the dish such that the papers did not touch the 
media. For both assays, the papers were then placed in scintillation vials for radioactivity counting.  
Measurement of glycogen synthesis – Cells were seeded into 12-well plates, treated for 1, 3, and 
5 days, and on the day of the experiment they were serum starved for 4 h. The wells were aspirated 
and given 0.2 µCi/mL of D-[14C] glucose either with or without 100 nM insulin and were incubated 
(37°C) for 2 h. Subsequently, each plate was placed on ice and the wells were aspirated and washed 
with cold PBS. After aspirating every well, 450 µl of 1 M KOH was added to each well and the 
plates were placed on a shaker for 15 min. Afterwards, the contents of the wells were placed into 
microtubes and heated at 65°C for 30 min. One hundred µl of type-2 glycogen from oyster 
dissolved in water (25 mg/ml), 80 µl of saturated  a2S 4, and 1.2 ml of 100% cold ethanol were 
then added to each of the tubes containing cell lysates. Tubes were vortexed and stored at -20°C 
overnight. Tubes were then centrifuged (7000 rpm) for 20 min. The supernatant was discarded and 
the remaining pellet was resuspended in 500 µl of distilled water. Four hundred µl of this mixture 
was placed in scintillation vials to count for radioactivity. 
Measurement of lactate production – Lactate production was measured using the Lactate 
Colorimetric Assay Kit according to the manufacturer’s instructions.  The cells were seeded into 
6-well plates and treated for 1, 3, and 5 days. Phenol red media would interfere with the 
microplate’s absorbance reading. For this reason, on the last day of media change, α-MEM media 
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without phenol red was used instead. On the day of the experiment, 0.5 ml of media extracts were 
collected into microtubes and stored at -80°C until ready for analysis. Each sample was 
deproteinized by passing them through 10 kDa filters. To measure lactate, a 96-well clear plate 
compatible with the spectrophotometer was used.  
Assessment of cell viability – The CellTiter-Glo® Luminescent Cell Viability Assay was used to 
conduct the experiment. Cells were seeded into 96-well clear plates that were compatible with the 
spectrophotometer and were treated for 1, 3, and 5 days. On the last day of media change, 50 µl of 
α-MEM media without phenol red was used in each well instead. ATP quantity in media was 
determined according to the manufacturer’s instructions. ATP media content is directly 
proportional to the number of metabolically active cells present.   
Western Blotting Analysis – Cells were seeded into 6-well plates and treated for 1, 3, and 5 days. 
On the day of lysis, wells were aspirated and washed with PBS. A lysis buffer that contains 25 
mM NaCl, 1 mM MgCl2, 2.7 mM KCl, 25 mM Tris-HCl, 10% glycerol, and 1% Triton was made. 
Protease and phosphatase inhibitors were added to the buffer and 100 µl of this buffer was added 
to each well. Cells were then further mechanically broken down using a 23-gauge needle and a 1 
ml syringe. Samples were then diluted 1:1 (v/v) with 2x Laemmli sample buffer. Samples were 
subsequently loaded and run through a gel, transferred onto a PVDF membrane, probed against 
the primary (1:1000 dilution) and secondary (1:2000 dilution) antibody of choice, and then 
developed in a dark room using Immobilon HRP substrate. The primary antibodies used were as 
follows: P‐AKT (60 kDa, Cat # 9271); AKT (60 kDa, Cat # 9272); P‐GS (85-90 kDa, Cat # 3891); 
GS (84 kDa, Cat # 3886); P‐GSK3α (51 kDa, Cat # 9327); GSK3α/β (51 and 46 kDa, Cat # 5676); 
PGC‐1α (100 kDa, Cat # AB3242); P‐AMPK (62 kDa, Cat # 2535); AMPK (62 kDa, Cat # 2532); 
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CPT1b (87 kDa, Cat # PB9491); β‐actin (45 kDa, Cat # 4967) served as a loading control. The 
Scion Image program was used to perform densitometry analyses on all developed blots.  
RNA isolation and quantitative PCR – Cells were seeded into 6-well plates and treated for 1, 3, 
and 5 days. The following day, the wells were aspirated and washed with PBS. The TRIzolTM 
protocol for cells was followed to extract RNA. cDNA was synthesized with 2 µg of RNA using 
the EasyScriptTM cDNA Synthesis Kit. cDNA synthesis was completed at 50°C for 50 min and 
then the reaction was stopped by heating the samples at 85°C for 5 min. Using a 96-well plate, 4 
μl of cDNA, 0.4 μl of the primer of choice, 10 μl of EvaGreen qPCR Mastermix, and 5.6 μl of 
RNase-free water was placed into each well. The plate was then centrifuged at 2500 rpm for 5 min 
at 4°C and amplified according to the following conditions: 95°C (10 min); 40 cycles of 95°C (15 
s), 60°C (60 s). All genes were normalized to TBP. The ΔΔCt method was used to determine the 
difference in gene expression between groups134. The primers used were as follows: TBP forward 
(TAC AGG TGG CAG CAT GAA GTG ACA) and reverse (AAC CAA CAA TCA CCA GCA 
GCA GTG); FAS forward (AAG GCA TCA CCA TAG CTA CAG CCT) and reverse (TAT GCT 
TCT CAC AGT GGC CAC ACA); CD40 forward (AGA TTA TCC CGG TCA CAA CAC) and 
reverse (CTG AGA TGC GAC TCT CTT TAC C); IL6r forward (TGG CAA CCT TAG TGC 
TCA TT) and reverse (TGT CTG CTC CAG CTT GTT AC); NF-κB forward (TCC AGC TGC 
TAT TGG ATT ACA C) and reverse (GGG ACT GCG ATA CCT TAA TGA C); TLR4 forward 
(ACC TAA GGA GAG GAG GCT AAG) and reverse (GGT AAC TGC AGC ACA CTA CA) 
and TNFR2 forward (CCA TGC TCA CAG ATT CCA CA) and reverse (GAC CTA ACA AGT 
CTG TCC CAA G).  
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Statistical analyses – The GraphPad Prism statistical software was used for statistical analyses.  
One- and two-way ANOVA with Bonferroni post-hoc tests were used to compare differences 
between conditions. Statistical significance was set at p <0.05.  
 
Results 
Effects of DHA and EPA on glucose uptake, glycogen synthesis, glucose oxidation, and 
lactate production – Under basal conditions with DHA treatment, glucose uptake remained 
unchanged (Figure 1A), unlike EPA treatment which led to a 39% increase in glucose uptake 
exclusively after 5 days (Figure 1B). With insulin stimulation, DHA resulted in an 18% reduction 
in glucose uptake only after 3 days, whereas EPA treatment led to no change for all time points. 
DHA and EPA treatment produced no change in basal glycogen synthesis (Figure 1 C, D 
respectively). Insulin-stimulated glycogen synthesis increased by 19% and 27% only after 1 day 
of DHA and EPA treatment respectively. The effect of insulin on glucose uptake and glycogen 
synthesis was maintained for all time points for DHA and EPA. DHA increased glucose oxidation 
by 70%, 70%, and 54% after 1, 3, and 5 days of treatment, respectively (Figure 1E). On the other 
hand, EPA’s influence was blunted with a 58% increase in glucose oxidation that was only 
maintained for 1 day of treatment (Figure 1F). To assess alternative fates of glucose, lactate 
production in L6 myoblasts was measured. With DHA treatment, there was no change in lactate 
production (Figure 1G). On the other hand, EPA has shown to increase lactate production across 
all time points with significance being reached only after three and five days of treatment with 
18% and 26% increases respectively (Figure 1H). 
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Effects of DHA and EPA on insulin signaling – In order to evaluate the impact of ω-3 fatty acids 
on the insulin signalling pathway, western blotting was conducted to assess phosphorylated and 
total AKT, GSK3α, and GS proteins. DHA treatment significantly increased insulin-stimulated 
phosphorylation of AKT after 5 days by 51% and remained unaffected under basal conditions 
(Figure 2A). EPA exposure led to no change in either basal or insulin-stimulated AKT 
phosphorylation (Figure 2D). After 1 day of DHA treatment, insulin-stimulated GSK3α 
phosphorylation was elevated by 92%, whereas no change was reported under basal conditions 
(Figure 2B). EPA caused no alteration in GSK3α phosphorylation with and without insulin (Figure 
2E). DHA and EPA had no effect on GS phosphorylation under basal and insulin-stimulated 
conditions (Figure 2 C, F respectively). Lastly, the effect of insulin was maintained for AKT and 
GSK3α phosphorylation, but not for GS.  
Effects of DHA and EPA on palmitate oxidation, AMPK phosphorylation and PGC-1α and 
CPT1b content – DHA increased palmitate oxidation by 81%, 55%, and 64% after 1, 3, and 5 
days of treatment respectively (Figure 3A). In contrast to DHA, EPA led to a 69% increase in 
palmitate oxidation that lasted for only 1 day (Figure 3B). To unravel the molecular mechanisms 
that are implicated in these functional changes, western blotting was done with L6 skeletal muscle 
cells. DHA exposure led to a uniform 6-fold, 7.8-fold, and 5.2-fold increases in the 
phosphorylation of AMPK with 1, 3, and 5 days of treatment respectively (Figure 3C). The content 
of CPT1b increased by 2.1-fold after both 1 and 5 days of DHA treatment (Figure 3D). On the 
other hand, EPA treatment showed no effect on AMPK phosphorylation (Figure 3F) and CPT1b 
content (Figure 3G). The content of PGC-1α was augmented by 5.9-fold, 5.3-fold, and 5.2-fold 
after 1, 3, and 5 days of DHA treatment respectively (Figure 3E). Following 1 day of EPA 
treatment, PGC-1α content increased by 2.3-fold (Figure 3H).  
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Effects of DHA and EPA on the mRNA expressions of IL-6R, TNFαR, CD40, TLR4, FAS, 
and NF-κB – To assess the anti-inflammatory role that ω-3 fatty acids can have directly on L6 
skeletal muscle cells, PCR was done on several inflammatory genes. There was no effect of DHA 
on the mRNA expression of IL-6R (Figure 4A), whereas EPA led to a 39% reduction that lasted 
for 1 day (Figure 4B). TNFαR mRNA expression was decreased by 50%, 50%, and 55% after 1, 
3, and 5 days of DHA treatment respectively (Figure 4C). However, EPA resulted in a 53% 
reduction in TNFαR mRNA expression that was maintained for 1 day (Figure 4D). CD40 mRNA 
expression was decreased by 42%, 59%, and 49% after 1, 3, and 5 days of DHA treatment 
respectively (Figure 4E). On the contrary, CD40 was decreased by 56% when L6 cells were treated 
with EPA exclusively with 1 day of treatment. (Figure 4F). TLR4 mRNA expression decreased 
only after 1 and 5 days of DHA treatment by 21% and 33% respectively (Figure 5A). Conversely, 
EPA treatment reduced TLR4 mRNA expression after 1, 3, and 5 days by 45%, 39%, and 43% 
respectively (Figure 5B). FAS mRNA expression decreased after three and five days of DHA 
treatment by 53% and 51% respectively (Figure 5C). On the other hand, EPA produced a 60% 
decrease in the mRNA expression of FAS, lasting for only 1 day (figure 5D). DHA treatment 
decreased the mRNA expression of NF-κB by 57%, 42%, and 47% after 1, 3, and 5 days 
respectively (Figure 5E), as opposed to EPA that led to no change (Figure 5F).  
Effects of DHA and EPA on cell viability – The concentration of ATP in media was measured 
to assess the cell viability of a time-course ω-3 fatty acid treatment. Exposure of DHA (Figure 6A) 
and EPA (Figure 6B) to L6 cells have led to no change in ATP production.  
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Discussion 
Herein, we provide evidence for the differential effects of EPA and DHA on glucose and 
fat metabolism, as well as their ability to reduce the expression of inflammatory genes in skeletal 
muscle cells. It has previously been shown that human rhabdomyosarcoma cells treated with ω-3 
fatty acids for 24 hours and 48 hours can lead to an upregulation of PGC1-α and GLUT4 mRNA 
expression as well as increased mitochondrial staining and basal metabolic rate. However, this 
study used a combined ω-3 treatment which prevented an in-depth analysis of their differential 
effects19. By studying the ω-3 fatty acids independently, we found that DHA consistently increased 
the rates of glucose and palmitate oxidation, whereas EPA increased lactate production and only 
transiently elevated palmitate oxidation in skeletal muscle cells. Furthermore, DHA promoted 
AMPK phosphorylation and increased PGC1-α and CPT1b contents, which are compatible with 
enhanced oxidative capacity in skeletal muscle cells. These findings are in agreement with 
previous studies demonstrating that the administration of ω-3 fatty acids to HF-fed mice reversed 
hepatic insulin resistance in wild-type, but not in AMPKα2 knockout mice135. Thus, it appears that 
AMPK and its downstream proteins are important targets for DHA in both skeletal muscle and 
liver. Previous studies have also demonstrated that treatment of C6 glioma cells with EPA led to 
the upregulation of transcription factors responsible for mitochondrial biogenesis such as TFAM, 
PGC1α, and NRF1136. Indeed, our study found an increased content of PGC-1α in L6 cells treated 
with EPA. Together, our findings suggest that EPA and DHA operate through PGC-1α-mediated 
enhancement of skeletal muscle mitochondrial oxidative capacity.  
It has been reported that obese and type-2 diabetic patients have fewer mitochondria with 
impaired bioenergetic capacity in their skeletal muscles137. This makes it particularly challenging 
for these subjects to reverse the damaging effects of lipid accumulation and inflammation within 
skeletal muscle tissue. The whole-body insulin-sensitizing effect of ω-3 fatty acids have been 
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attributed to a variety of factors including enhanced oxidative capabilities of adipose138, hepatic139, 
and muscle tissue10, as well as promoting effective cross-talk between these peripheral 
tissues140,141. Our study provides additional support for the powerful and direct impact that DHA, 
and to some extent, EPA, have on skeletal muscle cell oxidative metabolism19,142. We have also 
found that EPA and DHA’s effects were not mediated through alterations in the insulin signaling 
pathway. Interestingly, Aas et al. found that glucose uptake and oxidation as well as GLUT1 
mRNA expression was increased in human myotubes; however, this study used a 
supraphysiological EPA concentration of 0.6 mM for 1 day21. On the contrary, our study explored 
a physiological 50µM concentration and a treatment time of up to 5 days that is more representative 
of long term ω-3 fatty acid consumption. We found that neither AKT, GSK3α, and GS 
phosphorylation nor glucose uptake and glycogen synthesis were affected in L6 myoblasts exposed 
to either DHA or EPA. Indeed, ω-3 fatty acids have been shown to reverse insulin resistance in 
Goto-Kakizaki diabetic rats143 and in palmitate-induced insulin resistant C2C12 myotubes144. 
Thus, it is possible that DHA and EPA can improve insulin signaling under pathological conditions 
(e.g. type 2 diabetes), but not in intact normal-functioning skeletal muscle cells, such as the ones 
used in this study. Importantly, ATP production did not change with the administration of DHA 
and EPA and cell viability was preserved under all conditions. This indicates that the lack of an 
effect on insulin signalling was not due to a potential toxic effect of these fatty acids on skeletal 
muscles cells.  
As mentioned previously, proinflammatory mediators can cause dysregulation of glucose 
and fat metabolism and can lead to tissue-specific insulin resistance. Indeed, individuals with type-
2 diabetes or glucose intolerance have higher rates of IL-6, TLR4, and NF-κB expression in 
skeletal muscle as compared to healthy controls145. Rats that were fed a high fructose diet had 
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higher levels of TNF-α within skeletal muscle which triggered mitochondrial impairment and 
insulin resistance146. Additionally, when TLR is activated within skeletal muscle it leads to the 
translocation of NF-κB to the nucleus and the transcription of inflammatory genes such as TNF-α 
and IL-6147. Besides being activated by bacterial agonists as part of the innate immune response, 
polyunsaturated fatty acids can also serve as ligands for TLR4148. Most cell culture studies that 
explored the anti-inflammatory effects of ω-3 fatty acids have done so using an inflammation-
induced model. For instance, when C2 mouse skeletal myoblasts were treated with 50 µM EPA 
for 72 hours, the detrimental effects of palmitate and TNF-α on cell viability and differentiation 
were mitigated128. DHA treatment of C2C12 myotubes has also been shown to attenuate the 
production of palmitate-induced pro-inflammatory cytokines such as MCP-1 and IL-6149. 
Although EPA and DHA’s anti-inflammatory effects are evident, there is limited evidence to 
support the notion that these effects could be maintained under non-inflammatory conditions. In a 
separate study, C2C12 myotubes that were treated with either EPA or DHA at varying 
concentrations (400 µM – 600 µM) showed decreased IκBα phosphorylation and therefore reduced 
NF-κB translocation to the nucleus23. Although this is indicative of an anti-inflammatory effect, 
this study used non-physiological ω-3 fatty acid concentrations. Thus, in our study, we found the 
mRNA expression of key inflammatory genes such as NF-κB, CD40, TNF-αR, TLR4, and FAS to 
be significantly downregulated with 50 µM DHA treatment. On the other hand, 50 µM EPA 
treatment resulted in reduced expression in IL-6, CD40, TNF-α, TLR4, and FAS, but not in NF-
κB. Evidently, these ω-3 fatty acids exert a powerful anti-inflammatory effect on L6 skeletal 
muscle cells, which may be of value for conditions that are characterized by chronic inflammation 
such as in obesity. 
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With respect to the ability of skeletal muscle cells to respond to inflammatory mediators, 
our gene expression data also indicates that EPA had a milder anti-inflammatory effect than did 
DHA. When treated with EPA, muscle mRNA expression of IL-6, CD40, TNF-α, and FAS was 
diminished for only 1 day and NF-κB remained entirely unaffected. On the other hand, DHA 
induced long-term downregulation of the mRNA expression of NF-κB, CD40, TNF-α, TLR4, and 
FAS. The distinct effects that DHA and EPA exert on substrate metabolism and the expression of 
inflammatory genes in L6 muscle cells can be at least partially attributed to DHA having a greater 
degree of unsaturation relative to EPA, which can potentially facilitate its utilization by peripheral 
tissues. In fact, as compared to EPA and other polyunsaturated fatty acids, DHA has shown higher 
levels of incorporation into skeletal and cardiac muscle membranes150. A greater degree of 
unsaturation within the phospholipid bilayer can also result in greater membrane fluidity among 
cells treated with DHA. These differences can directly impact ω-3 fatty acid bioavailability and 
can explain the higher relative potency of DHA on L6 myoblast metabolism. Therefore, on a 
molecular level, EPA, and especially DHA, exert their effects on L6 muscle cells by 
downregulating inflammatory pathways as well as directly upregulating proteins involved in 
oxidative metabolism. The increased rate of substrate utilization that is provoked mainly by DHA 
could lead to the decreased accumulation of harmful intramuscular lipid intermediates, which may 
be of therapeutic value against the development of skeletal muscle and whole-body insulin 
resistance. 
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Figure 4: Summary of findings. Phosphorylation of AKT, GSK, and GS as well as glucose uptake and 
glycogen synthesis showed no changes with EPA and DHA. Lactate production was unchanged with DHA, 
but showed a sustained increase with EPA treatment. PAMPK, CPT1b, and PGC1-α are all upregulated 
with DHA treatment which reflects the sustained increase in glucose and palmitate oxidation. On the 
contrary, there was no change in PAMPK and CPT1b, but a transient increase in PGC1-α lasting for 1 day 
which reflected the blunted glucose and palmitate oxidation with EPA treatment. DHA led to a long-term 
reduction in the mRNA of inflammatory genes, whereas EPA had a short-term reduction.  
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Figure 1: Effects of DHA and EPA on glucose metabolism in L6 skeletal muscle cells. After treating 
cells with EPA, DHA, or control for 1, 3, and 5 days, glucose uptake (A and B) and glycogen synthesis (C 
and D) was measured and showed no change under basal and insulin stimulated conditions. Glucose 
oxidation increased with 1, 3, and 5 days of DHA treatment (E), but only increased with 1 day of EPA 
treatment (F). Lactate media content was found to increase with EPA (H), but not DHA (G). *P<0.05 vs. 
0 days of treatment, #P<0.05 vs. basal. Two-way and one-way analysis of variance (ANOVAs), n=6-12.  
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Figure 2: Effects of DHA and EPA on insulin signalling in L6 skeletal muscle cells. Phosphorylation and 
contents of AKT (A and D), GSKα (B and E), and GS (C and F) with DHA and EPA treatment. *P<0.05 
vs. 0 days of treatment, #P<0.05 vs. basal. Two-way ANOVA, n=4-6. 
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Figure 3: Effects of DHA and EPA on palmitate oxidation, AMPK phosphorylation, and contents of 
CPT1b and PGC1α in L6 skeletal muscle cells. Palmitate oxidation increased with 1, 3, and 5 days of 
DHA treatment (A), but only with 1 day of EPA treatment (B). AMPK phosphorylation (C) and CPT1b 
(D) and PGC1α (E) contents also increased under all time points with DHA treatment. EPA treatment led 
to no change in AMPK phosphorylation (F) and CPT1b content (G) and an increase in PGC1α content 
after 1 day (H). *P<0.05 vs. 0 days of treatment. One-way ANOVA, n=4-6. 
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Figure 4: Effects of DHA and EPA on mRNA expressions of IL-6R, TNFαR, and CD40 in L6 skeletal 
muscle cells. IL-6R mRNA expression decreased with 1 day of EPA treatment (B), but no change 
occurred with DHA treatment (A). TNFαR (C) and CD40 (E) mRNA expression decreased with 1, 3, and 
5 days of DHA treatment, however, EPA treatment led a decrease only after 1 day (D and F). *P<0.05 vs. 
0 days of treatment. One-way ANOVA, n=4-6. 
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Figure 5: Effects of DHA and EPA on mRNA expressions of TLR-4, FAS, and NF-κB in L6 skeletal 
muscle cells. TLR-4 mRNA expression decreased with 1 and 5 days of DHA treatment (A) and 1, 3, and 
5 days of EPA treatment (B). DHA treatment reduced mRNA expression of FAS after 3 and 5 days (C), 
but EPA only did so after 1 day (D). NF-κB mRNA expression decreased under all time points with DHA 
treatment (E), and had no change with EPA treatment (F). *P<0.05 vs. 0 days of treatment. One-way 
ANOVA, n=4-6. 
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Figure 6: ATP concentration in media of L6 skeletal muscle cells treated with DHA and EPA. *P<0.05 
vs. 0 days of treatment. One-way ANOVAs, n=6.  
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Conclusion and future directions 
In our study, we show that besides exerting anti-inflammatory effects, DHA and EPA 
directly regulated glucose and fat metabolism in L6 skeletal muscle cells. This was demonstrated 
through increased glucose and palmitate oxidation as well as upregulation of proteins that are 
involved in these processes. We also observed that, relative to EPA, DHA had a more potent 
anti-inflammatory effect and was better able to upregulate skeletal muscle energy metabolism. 
Thus, by directly enhancing glucose and fat oxidation, DHA may increase glucose disposal and 
protect skeletal muscle cells against lipotoxicity. 
By testing DHA and EPA separately, we were able to identify their differential effects. 
However, as mentioned previously, in nature, polyunsaturated fatty acids do not exist in 
isolation, but rather in a mixed form. For this reason, future experiments should address whether 
combining EPA and DHA together would produce an additive effect or if they interact in an 
alternative manner. To expand this experiment, another treatment condition should include a 
mixture that combines EPA, DHA, and an ω-6 fatty acid, such as arachidonic acid. There is 
extensive literature that recommends a dietary ω-6: ω-3 ratio of 1:1. It would be important to 
understand whether ω-3 fatty acids can effectively mitigate the proinflammatory and insulin 
resistant states that are associated with ω-6 fatty acids.  
Another important direction that requires further exploration is DHA’s potential 
capability of restoring muscle energy metabolism dysfunction. To accomplish this, insulin 
resistant skeletal muscle cells should be treated with DHA and subsequently assessed for insulin 
sensitivity, glucose uptake, and glucose oxidation. Alternatively, a combination DHA + saturated 
fat treatment can be implemented to determine whether DHA can prevent the onset of saturated 
fat-induced lipotoxicity. Therefore, future experiments should focus on pairing ω-3 fatty acids 
50 
 
with other fats to identify how they interact with one another in the context of skeletal muscle 
energy metabolism.   
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Appendix 
Appendix A: Detailed experimental methods 
Determination of FFA concentration using Wako HR series NEFA-HR kit 
1. Dissolve 5.8mg of reagent A for every 1ml of solvent A. 
2. Dissolve 10.4 mg of reagent B for every 1ml of solvent B.  
3. Pipette sample and standard into cuvettes.  
4. Add 0.5 mL of the prepared solution A into each cuvette and incubate for 5 min in 37˚C 
water bath. 
5. Remove cuvettes from water bath, add 0.25 ml of solution B into each cuvette, and 
incubate for 5 min in 37˚C water bath. 
 
6. Read the absorbance at 550 nm 
7. NEFA concentration is calculated as follows: Cs = As/AStd*1 (mEq/L) 
a. Cs = sample concentration, As = absorbance of 245 sample at 550 nm, AStd = 
absorbance of standard solution at 550 nm. mEq/L = mmol/L. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cuvette # Name 1mEq/L NEFA 
Standard 
H2O 
1 Blank 0 12.5 μl 
2 Low standard  6.25 μl 6.25 μl 
3 Standard 12.5 μl 0 
4 Sample 12.5 μl 0 
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Western blotting 
Western blot buffers: 
10X Running Buffer- pH 8.3: 
 144 g Glycine  
 10 g SDS  
 30.34 g Tris base 
 1 L ddH2O 
 Store at room temperature 
1X Running Buffer- pH 8.3:  
 200 ml 10X running buffer 
 1800 ml ddH2O  
 Store at room temperature 
10X Transfer Buffer- pH 8.3:  
 30.3 g Tris base 
 144 g Glycine  
 1 L ddH2O 
 Store at 4°C 
1X Transfer Buffer- pH 8.3:  
 150 ml 10X transfer buffer 
 300 ml Methanol 
 1050 ml ddH2O  
 Store at -20°C 
10X Wash Buffer: 
 60.57 g Tris base 
 87.66 g NaCl  
 1 L ddH2O 
 Store at 4°C 
1X Wash Buffer: 
 400 ml 10X wash buffer 
 3600 ml ddH2O 
 Add 500 μL/L each of Tween-20 and NP-40 
 Mix solutions and store at 4°C 
Blocking Buffer:  
 3% BSA (3 g/100 ml) in 1X wash buffer 
 Store at 4°C 
Antibody Buffer: 
 1°antibody: 
o Usually 1:1000 (v/v) dilution of 1°antibody in blocking buffer 
o 0.02% (v/v) sodium azide.  
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 2°antibody:  
o Usually 1:2000 (v/v) dilution of 2°antibody in blocking buffer 
Resolving Gel Tris Buffer- 1.5 M, pH 8.8: 
 90.86 g Tris base 
 500 ml ddH2O 
 Store at 4°C 
Stacking Gel Tris Buffer- 0.5 M, pH 6.8: 
 30.3 g Tris base  
 500 mL ddH2O  
 Store at 4°C 
10% SDS Solution:  
 2 g SDS 
 20 ml ddH2O 
 Store at room temperature 
10% APS Solution:  
 1 g APS 
 10 mL ddH2O 
 Store at -20°C 
Lysis Buffer: 
 25 mM Tris-HCl 
 25 mM NaCl-pH 7.4 
 1 mM MgCl2 
 2.7 mM KCl 
 1% Triton-X 
 10% glycerol 
 Aliquot and store at -20°C 
 Add protease and phosphatase inhibitors prior to use 
2X Laemmli Sample Buffer:  
 950 μl Laemmli sample buffer 
 50 μl βmercaptoethanol 
 Dilute sample 1:1 with sample buffer, incubate at 95°C for 5 min.  
Preparation of Cell Lysates: 
1. Seed cells into 6-well plates prior to the start of the treatment.  
2. On the day of lysis, aspirate cells and wash with PBS 
3. 150 μl of lysis buffer is to be added to each well and further broken down mechanically with 
a 23-gauge needle and a 1 mL syringe. 
4. Aliquot each sample for protein determination using Bradford method. Aliquot remainder 
and store at -80°C. 
Western Blotting Protocol: 
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Prepare 10% resolving and 4% stacking gels using the recipe below:  
Component Quantity (2 resolving gels- 
10%) 
Quantity (2 stacking 
gels- 4%) 
ddH2O 6.91 ml 3.92 ml 
30% Acrylamide- 37:5:1 5.67 ml 0.87 ml 
Tris-HCL- 1.5 M, pH 8.8 4.25 ml 0 ml 
Tris-HCL- 0.5 M, pH 6.8 0 ml 1.63 ml 
10% SDS 0.17 ml 65 μl 
TEMED 20 μl 10 μl 
10% APS 100 μl 50 μl 
 
Running gel: 
1. Remove samples from -80°C freezer and briefly centrifuge them  
2. Place gels into tanks and fill tanks with 1X running buffer 
3. Remove the green combs and pipette 6 μl of protein ladder into the very left-most well 
4. Pipette samples into the appropriate wells  
5. Close the container and turn on the voltage 110 V for approximately 2 h 
Transferring to membrane: 
1. Have 1X transfer buffer read and in -20°C.  
2. Fill a large dish with cold transfer buffer 
3. Soak equal-sized PVDF membranes in methanol for 1 min 
4. Have equal-sized filter papers foam pads ready 
5. Take the gels out of the tank and soak in transfer buffer and remove the glass plates 
6. Place the black side of the cassette down in the dish with transfer buffer Place a foam 
pad, 2 filter paper squares, followed by the gel, PVDF membrane, 2 more filter papers, 
and another foam pad. Close the cassette and place into transfer tank.  
7. Fill the tank up with 1X transfer buffer and put an ice pack into the transfer tank to 
maintain cold water temperature. Surround the transfer tank with ice to prevent 
overheating 
8. Turn on the voltage to 120 V for 2 h or 20 V for 18 h 
Probing the membrane: 
1. Place the membranes in containers that have 6 ml blocking buffer and leave on shaker for 
at least 1 h 
2. Replace blocking buffer with 1° antibody and leave on shaker for 2 h at room 
temperature or at 4°C overnight 
3. Replace the 1° antibody with 1X wash buffer and have it shaking at room temperature for 
50 minutes, replacing the wash buffer every 10 min 
4. Remove the wash buffer and add the 2° antibody for 1 h at room temperature 
5. Replace 2° antibody with the 1X wash buffer and repeat the washing procedure 
Developing the membrane: 
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1. Remove the wash buffer and incubate the membrane in 3 mL of chemiluminescence 
Millipore Luminata Forte Western HRP Substrate at room temperature for 2 min, making 
sure to shake the containers. 
2. Place the membranes inside the developing cassette. 
3. In the dark room, expose a piece of film to the membrane inside the cassette 
4. When ready, place film in developer solution, followed by a brief soak in water and then 
fixer solution to terminate the reaction.  
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Quantified Polymerase Chain Reaction (qPCR) 
RNA Isolation  
1. Seed cells into 6-well plates prior to the start of the treatment.  
2. On the day of lysis, aspirate wells and wash with PBS. 
3. Add 1 ml of Trizol™ reagent per well, pipette up and down to homogenize the samples. 
4. Place the samples into 2 ml microtubes and incubate at room temperature for 5 min. 
5. Add 0.2 ml of chloroform and vortex briefly.  
6. Incubate the sample at room temperature for 2-3 min. 
7. Centrifuge the samples at 13,000 rpm for 15 min. at 4°C.  
8. The sample will separate into a lower red phenol-chloroform phase, an interphase and a 
colourless upper phase. Transfer the aqueous upper phase into a new tube. 
9. Add 0.5 ml of 100% isopropanol to the aqueous phase and mix samples. 
10. Allow samples to incubate at room temperature for 10 min. and then centrifuge the 
samples at 13,000 rpm for 20 min. at 4°C. 
11. Discard the supernatant from the tube and wash the remaining pellet with 1 ml of 75% 
ethanol. Centrifuge the tube at 13,000 rpm for 20 min. at 4°C. Discard the ethanol.  
12. Air-dry the RNA pellet for 5-10 min.  
13. Resuspend the RNA pellet in RNAse-free water. 
14. Incubate RNA on heat block for 10 min at 60°C and quantify yield using the 
 ano ropTM machine. Store samples at -80°C. 
 
cDNA Synthesis 
1. Using the ABM EasyScript™ Reverse Transcriptase kit, combine 2 μg RNA with 1 μl of 
10 μM random primers and 1 μl of 10 mM dNTP mix. 
2. Incubate the mixture at 65°C for 5 min. and then place on ice for 1 min.  
3. Add 4 μl of 5X RT buffer, 0.5 μl of RNAseOFF Ribonuclease inhibitor, and 1μl of 
EasyScript™ RTase to sample. 
4. Mix components and centrifuge briefly.  
5. Incubate the samples at 25°C for 10 min, 50°C for 50 min. and 85°C for 5 min. 
6. Store the cDNA at -20°C.  
 
Real-Time qPCR  
1. Using an RNAse-free 96-well PCR plate, combine 4 μl cDNA, 0.4 μl primer solution, 10 
μl ABM EvaGreen qPCR mastermix, and 5.6 μl of RNase-free water into each well.  
2. Centrifuge the plate at 2500 rpm for 5 min. at 4°C. 
3. Complete real-time PCR analysis using the following amplification conditions: 95°C (10 
min); 40 cycles of 95°C (15 s), 60°C (60 s).  
4. Use TBP as a control gene to normalize the genes you are testing.  
5. Use the ΔΔCt method in order to determine relative differences in gene expression 
between treatment groups.  
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Lactate colorimetric assay 
Lactate content in media was measured using the Lactate Colorimetric Assay Kit from 
BioVision: 
1. Seed cells into 6-well plates prior to the start of the treatment.  
2. On last day of media change, α-MEM media without phenol red is to be used instead 
(phenol red media would interfere with the microplate’s absorbance reading) 
3. On day of experiment, extract 0.5ml of media from each well, place in liquid nitrogen, 
and then store at -80°C for future use.  
4. When ready, remove samples from freezer, and thaw on ice. Samples are to be 
deproteinized by centrifuging them through 10 kDa filters for 15 min at 4°C 
5. To measure lactate, a 96-well clear plate that is compatible with the spectrophotometer is 
required.  
6. To create standard curve: 10 µl of 100nmol/µl lactate standard must be added to 990 µl of 
lactate assay buffer. 0, 2, 4, 6, 8, and 10 µl of this standard solution should be placed into 
the 96-well plate and the volume adjust the volume to 50 µl with lactate assay buffer. To 
each standard well, add a reaction mix that contains 46 µl of lactate assay buffer, 2 µl of 
lactate enzyme mix, and 2 µl of probe.  
7. Add 2.5 µl of sample into separate wells and as with the standards, adjust the volume to 
50 µl and then add the reaction mix.  
8. Incubate the plate at room temperature for 30 min. shielded from light.  
9. Read the absorbance of the samples at 570nm. 
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Cell viability  
ATP content in media was measured using the CellTiter-Glo® Luminescent Cell Viability Assay: 
1. Seed cells into 96-well plates prior to the start of the treatment.  
2. On last day of media change, 50 µM α-MEM media without phenol red is to be used 
instead (phenol red media would interfere with the microplate’s absorbance reading). 
3. Incubate at room temperature for 30 min. 
4. Transfer 10 ml of CellTiter-Glo® buffer into the CellTiter-Glo® substrate to create a 
reaction mix 
5. To create a standard curve, prepare 0.01, 0.1, 0.25, 0.5, and 1 µM of ATP in α-MEM 
media without phenol red and load 50 µl into each well.  
6. Add 50 µl of the reaction mix to sample and standard wells 
7. Place on a shaker for 5 min. and incubate at room temperature for 10 min.  
8. Measure luminescence of the samples. (ATP media content is directly proportional to the 
number of metabolically active cells present).  
 
 
 
 
